Clinical Trials Browser

Multi-centric Castleman's Disease, Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, HIV Infections, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

Clinical Trials

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 1b Safety and Efficacy Study of TRU-016

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection